Ge Long Hui·2026-01-20 09:40Core Viewpoint - RAPT Therapeutics shares surged 63.5% in pre-market trading to $54.4 following the announcement that GlaxoSmithKline will acquire the company for $58 per share, valuing the equity at $2.2 billion, with an expected initial investment of $1.9 billion [1]. Group 1 - RAPT Therapeutics' market capitalization was less than $1 billion before the trading halt on Friday [1]. - The pre-market price of RAPT Therapeutics reached $54.4, reflecting a significant increase of 63.5% [1]. - The acquisition price of $58 per share represents a premium over the previous closing price of $32.19 [1]. Group 2 - The total market value of RAPT Therapeutics is reported at $973 million [2]. - The trading volume in the pre-market session was 430,100 shares [2]. - The stock has a 52-week high of $42.392 and a low of $5.665, indicating significant volatility [2].